Abstract: Novel mono-azide substituted rylene-imide derivatives, their use in methods for the detection of analytes and reagents kits for the detection of analytes comprising said novel mono-azide substituted rylene-imide derivatives.

Abstract: The present invention is based, in part, on assays we conducted that revealed compounds that may be used to treat or prevent diseases characterized by an abnormal or undesirable association of one protein with another.

Abstract: A method of identifying compounds as direct inhibitors of Keap1-Nrf2 interaction through high-throughput screening and lead development. The direct inhibitors of Keap1-Nrf2 interaction are more specific and free of various undesirable effects than existing indirect inhibitors, and are potential drug candidates of chemopreventive and therapeutic agents for treatment of various diseases or conditions involving oxidative stress and/or inflammation, including but not limited to cancers, diabetes, Alzheimer's, and Parkinson's. Novel compounds are identified and methods of preventing or treating diseases or conditions related to Keap1-Nrf2 interaction activity by use of the novel compounds identified or compositions containing such compounds are also disclosed.

Abstract: Disclosed are compounds effective for inhibiting cellular apoptosis and for protecting cells and tissues from the apoptotic effects of chemotherapeutic agents and/or ionizing radiation. Compounds of the invention act as agonists of the LPA2 receptor. Compounds of the invention comprise non-lipid benzoic acid derivatives. Further disclosed is a pharmacophore of LPA2 receptor.

Abstract: Disclosed is a polyimide prepolymer, an alignment film and a method for preparing the same, as well as a liquid display device. The polyimide prepolymer has a repeating unit as shown in Formula (1) and is capped with a capping agent having a phenylethynyl group: wherein Ar is selected from one of the structures of the following Formulae (2) and (3): and n is an integer of between 3 and 8.

Abstract: The present invention is directed to an improved process for the preparation of Compounds of Formula (I) or salts thereof which are useful in the treatment of HIV infection. In particular, the present invention is directed to an improved process for the preparation of (2S)-2-tert-butoxy-2-(4-(2,3-dihydropyrano[4,3,2-de]quinolin-7-yl)-2-methylquinolin-3-yl)acetic acid or salt thereof which is useful in the treatment of HIV infection.

Abstract: Novel mono-azide substituted rylene-imide derivatives, their use in methods for the detection of analytes and reagents kits for the detection of analytes comprising said novel mono-azide substituted rylene-imide derivatives.

Abstract: Novel mono-azide substituted rylene-imide derivatives, their use in methods for the detection of analytes and reagents kits for the detection of analytes comprising said novel mono-azide substituted rylene-imide derivatives.

Abstract: The present invention relates to high transmission yellow dye for LCD, dye dispersion comprising the dye, coloring composite comprising the dye dispersion, color filter comprising the coloring composite, and synthetic method thereof.

Abstract: Disclosed are compounds effective for inhibiting cellular apoptosis and for protecting cells and tissues from the apoptotic effects of chemotherapeutic agents and/or ionizing radiation. Compounds of the invention act as agonists of the LPA2 receptor. Compounds of the invention comprise non-lipid benzoic acid derivatives.

Abstract: The present invention relates to compounds of the formulae Ia and Ib in which the variables R, n, A, B, R1 and R2 are each as defined in the description. The present invention further relates to the use of compounds of the formula Ia or Ib or mixtures of compounds of the formulae Ia and Ib and/or isomers or mixtures of the isomers of the compounds of the formulae Ia and Ib as photosensitizers in solar cells and photodetectors, and to solar cells and photodetectors which comprise such compounds of the formula Ia or Ib or mixtures of compounds of the formulae Ia and Ib and/or isomers or mixtures of the isomers of the compounds of the formulae Ia and Ib as photosensitizers.

Abstract: The present invention is based, in part, on assays we conducted that revealed compounds that may be used to treat or prevent diseases characterized by an abnormal or undesirable association of one protein with another.

Abstract: The present invention relates to anti-cancer compounds, methods for their discovery, and their therapeutic use. In particular, the present invention provides analogs of the known anti-cancer compound amonafide, and structurally and functionally related compounds, and methods of using such compounds as therapeutic agents to treat a number of conditions associated with hyperproliferation.

Abstract: Provided are novel salts of 2-(1-azabicyclo-[2.2.2]oct-3-yl)-2,3,3a,4,5,6-hexahydro-1H-benz[de]isoquinolin-1-one, methods of using such salts, and processes for producing such salts.

Abstract: The present invention provides novel palonosetron free base in an amorphous form and crystalline form-G and processes for their preparation. The present invention also provides a process for the preparation of palonosetron hydrochloride from the novel palonosetron free base in an amorphous form and/or in crystalline form-G.

Abstract: The present invention relates to processes for the preparation of Form I and Form II of palonosetron hydrochloride. The present invention further relates to a method of determining the polymorphic forms of palonosetron hydrochloride using Fourier-Transform Infra-red (FTIR) method.

Abstract: Provided are metabolites of palonosetron that can be used in treating animals, particularly humans, of the formula (I): or a pharmaceutically acceptable salt or prodrug thereof; wherein R1 and R4 independently can be H, hydroxyl, or carbonyl; and wherein R3 can be Formule (II) or Formule (III).

Abstract: Disclosure is provided for benzimidazole derivative compounds that prevent, remove and/or inhibit the formation of biofilms, compositions including these compounds, devices including these compounds, and methods of using the same.

Abstract: The present invention provides a radical generator having a naphthalimide structure or a crosslinking agent and a photosensitive compound having a function as a radical generator. A photoradical polymerization initiator of the present invention comprises a compound (a) having only one naphthalimide structure-containing group in one molecule. The radial generator of the present invention comprises a compound (c) having two or more naphthalimide structure-containing groups in one molecule and also functions as a crosslinking agent. A first photosensitive compound of the present invention comprises a compound (d) having a naphthalimide structure-containing group and an ethylenic unsaturated group in one molecule. A second photosensitive compound of the present invention comprises a polymer (e) of one or more radical polymerizable compounds containing the compound (d).

Abstract: The present invention relates to compounds of the formulae Ia and Ib in which the variables R, n, A, B, R1 and R2 are each as defined in the description. The present invention further relates to the use of compounds of the formula Ia or Ib or mixtures of compounds of the formulae Ia and Ib and/or isomers or mixtures of the isomers of the compounds of the formulae Ia and Ib as photosensitizers in solar cells and photodetectors, and to solar cells and photodetectors which comprise such compounds of the formula Ia or Ib or mixtures of compounds of the formulae Ia and Ib and/or isomers or mixtures of the isomers of the compounds of the formulae Ia and Ib as photosensitizers.

Abstract: Disclosed herein are compounds represented by the structural formula: therapeutic methods, compositions, and medicaments related thereto are also disclosed.

Abstract: The present invention provides crystalline forms of Palonosetron hydrochloride, processes for their preparation and pharmaceutical compositions containing such crystalline forms of Palonosetron HCl.

Abstract: Material for thermal insulation including an aerogel obtained by drying an organogel prepared from the pseudopeptides of formula (I). in which R represents a side chain of an amino acid, R1 represents a (C1-C8)alkyl, (C1-C8)alkoxy, aryl, aryloxy, or glycoside group, n=1 or 2 and A represents an aromatic group with one or more rings.

Abstract: This invention relates to an improved and scalable process for the preparation of substantially pure palonosetron and its acid addition salts, in particular hydrochloride (I) which comprises of, (a) converting intermediate (IIa) as such or as its freebase (II) to a crude mixture of diastereomeric palonosetrons (VIII) or (VIIIa) contaminated with varying amounts of unconverted intermediate (II) or (IIa) via hydrogenation under pressure with an appropriately chosen hydrogenation catalyst in an suitable organic solvent. (b) making the resulting crude mixture of diastereomeric palonosetrons (VIII) or (VIIIa) contaminated with varying amounts of unconverted intermediate (II) or (IIa) substantially free from (II) or (IIa) via halogenation reaction.

Abstract: Use of benzimidazole-derived compounds of formula (I) according to the following structure, wherein x is a heteroatom selected from N, S, O, P, SO, SO2 and SO3, preferably from N, S and SO3 and most preferably from N and SO3; n may be 0 or 1, R1 is a group selected from formula (II) and formula (III) and R2 is a group selected from H and formula (IV) since the aforesaid serves for the production of a formulation used as a specific marker in the case of neurodegenerative diseases and tau pathologies.

Abstract: Aromatic non-polymeric amic acid salts are designed to be thermally converted into corresponding arylene diimides. These aromatic, non-polymeric amic acid salts can be used to prepare semiconducting thin films that can be used in various articles including thin-film transistor devices that can be incorporated into a variety of electronic devices. In this manner, the arylene diimide need not be coated but is generated in situ from a solvent-soluble, easily coated aromatic, non-polymeric amic acid salt at relatively lower temperature because the cation portion of the amic acid salt acts as an internal catalyst.

Abstract: An amic acid or amic ester precursor can be applied to a substrate and thermally converted into a thin organic semiconducting layer of the corresponding arylene diimide. This semiconducting layer can be used in various semiconductive articles such as organic light emitting diode (OLED), photodetector, sensor, logic circuit, memory element, capacitor, photovoltaic (PV) cell, or electronic devices. In this manner, the arylene diimide need not be coated but is generated in situ from a solvent-soluble and easily coated precursor compound.

Abstract: Processes for the preparation of palonosetron hydrochloride and its crystalline forms.

Abstract: Novel mono-azide substituted rylene-imide derivatives, their use in methods for the detection of analytes and reagents kits for the detection of analytes comprising said novel mono-azide substituted rylene-imide derivatives.

Abstract: A hydroxyquinolone compound formulated as a fluorescent dye for protein detection, assay, quantitation, etc. The hydroxyquinolone compound may be modified, for example, by adding or removing sulfate groups, changing hydrocarbon chain lengths, etc. to result in more desirable properties such as enhanced binding to basic proteins, enhanced solubility, etc. The dye has enhanced sensitivity over commercially available protein stains, and may be used to stain proteins in solution, proteins separated on gels, proteins transferred to solid supports, etc. Methods of using the dyes are also disclosed.

Abstract: This invention relates to an improved and scalable process for the preparation of substantially pure palonosetron and its acid addition salts, in particular hydrochloride (I) which comprises of, (a) converting intermediate (IIa) as such or as its freebase (II) to a crude mixture of diastereomeric palonosetrons (VIII) or (VIIIa) contaminated with varying amounts of unconverted intermediate (II) or (IIa) via hydrogenation under pressure with an appropriately chosen hydrogenation catalyst in an suitable organic solvent. (b) making the resulting crude mixture of diastereomeric palonosetrons (VIII) or (VIIIa) contaminated with varying amounts of unconverted intermediate (II) or (IIa) substantially free from (II) or (IIa) via halogenation reaction.

Abstract: Protein dyes whose molecular structure is that of a coumarin moiety coupled to a quaternary ammonium heterocycle through a vinyl or polyvinyl linkage demonstrate the ability to associate with proteins in a non-covalent, non-specific manner at low pH, where the associated form displays a significantly higher fluorescence emission than the unassociated form. This makes the dyes useful as selective labels for proteins at the low pH and eliminates the need for the removal of extraneous components from the medium in which the proteins reside prior to detection.

Abstract: The present invention relates to anti-cancer compounds, methods for their discovery, and their therapeutic use. In particular, the present invention provides analogs of the known anti-cancer compound amonafide, and structurally and functionally related compounds, and methods of using such compounds as therapeutic agents to treat a number of conditions associated with hyperproliferation.

Abstract: The present invention provides novel palonosetron free base in an amorphous form and crystalline form-G and processes for their preparation. The present invention also provides a process for the preparation of palonosetron hydrochloride from the novel palonosetron free base in an amorphous form and/or in crystalline form-G.

Abstract: The present invention relates to substituted pyrrolidine compounds of general formula (I), methods for their preparation, medicaments comprising these compounds as well as their use for the preparation of a medicament for the treatment of humans and animal.

Abstract: The invention relates to novel N-substituted imides and polymerizable compositions comprising these N-substituted imides. The invention further relates to the use of N-substituted imides as polymerization initiators.

Abstract: The invention relates to compounds having pharmacological activity towards the 5-HT7 receptor, and more particularly to some 2,2a,4,5-tetrahydro-1H-3-aza-acenaphthylen substituted sulfonamide compounds, to processes of preparation of such compounds, to pharmaceutical compositions comprising them, and to their use for the treatment and or prophylaxis of a disease in which 5-HT is involved, such as CNS disorders.

Abstract: A bis(indolestyryl) compound. The bis(indolestyryl) compound has formula (I): wherein A and B comprise benzene, naphthalene, or heterocyclic ring containing O, S, or N, R1 and R1? are H, halogen, C1-5 alkyl, nitro, ester, carboxyl, sulfo, sulfonamide, amide, sulfo ester, C1-3 alkoxy, amino, alkylamino, cyano, C1-6 alkylsulfonyl, or C2-7 alkoxy carbonyl, R2, R2?, R3, and R3? comprise H, C1-6 alkyl, C6-18 aryl, C2-6 alkenyl, C3-6 cycloalkenyl, or C3-6 cycloalkyl, R4 is H, C1-5 alkyl, hydroxyl, halogen, or alkoxy, R5 and R5? comprise H, halogen, C1-5 alkyl, nitro, C1-3 alkoxy, amino, cyano, C1-6 alkylsulfonyl, or C2-7 alkoxy carbonyl, W comprises oxygen, sulfur, selenium, —NR, or —C(CH3)2, n is 1˜18 and Z1 and Z2 are different and comprise an anion or an anionic organometallic complex with +1 or +2 valence, wherein R bonded to nitrogen is C1-4 alkyl.

Abstract: The invention relates to the inhibition of histone deacetylase. The invention provides compounds and methods for inhibiting histone deacetylase enzymatic activity. The invention also provides compositions and methods for treating cell proliferative diseases and conditions.

Abstract: The invention relates to compounds having pharmacological activity towards the 5-HT7 receptor, and more particularly to some 2,2a,4,5-tetrahydro-1H-3-aza-acenaphthylen substituted sulfonamide compounds, to processes of preparation of such compounds, to pharmaceutical compositions comprising them, and to their use for the treatment and or prophylaxis of a disease in which 5-HT is involved, such as CNS disorders.

Abstract: The present invention has for an object brightening cationic naphthalene dyes of formula (I) and colorants for keratin fibers, particularly human hair, containing these compounds

Abstract: The present invention has for an object novel naphthalene dyes of formula (I) and colorants for keratin fibers, particularly human hair, containing these compounds.

Abstract: The present invention relates to intermediates useful in the synthesis of Dolasetron and synthetic precursors thereof, as well as to processes for obtaining them. In addition, it refers to the hydrochloric salt of Dolasetron and polymorphic forms of Dolasetron and precursors thereof.

Abstract: The bisnaphthalimidopropyl derivatives with anti-parasitic and anti-cancer activity. Bisnaphthalimidopropyl derivatives (A) BNIPPut, BNIPDapen, BNIPDhex, BNIPDahep, BNIPDaoct, BNIPDanon, BNTPDadec, BNIPDadod, BNPDpta, BNIPDeta were synthesized in yields ranging from 50-70 and their cytotoxicity against colon cancer cells (CaCo-2) and the parasite Leishmania infantum determined using the MTT assay and by luciferase activity present in parasite, respectively. Cytotoxicity within CaCo-2 cells was manifested with IC50 values between 0.3 and 22 m M after 48 h of compounds incubation. Against Leishmania infantum, IC50 values were encompassed within a narrower concentration range of 0.39-2.09 m M, for pro-mastigote form, and between 5.24 and 17.42 m M, for axenic amastigote and between 2.43 and 9.52 m M, for intracellular amastigote forms.

Abstract: The present invention provides novel fluorophore compounds.

Abstract: The invention relates to novel N-substituted imides and polymerizable compositions comprising these N-substituted imides. The invention further relates to the use of N-substituted imides as polymerization initiators.

Abstract: A light-emitting compound that has excellent carrier transportation properties and that can exhibit long wavelength light is disclosed. Further, a method for manufacturing the light-emitting compound in a high yield is disclosed. The disclosed light-emitting compound is a pyran derivative as represented by general formula 1: wherein A1 and A2 are individually a ?-conjugated system group having 6 to 16 conjugating carbon atoms; X1 is a dialkylamino group; and Y1 is a diarylamino group or an alkylarylamino group.

Abstract: The present application relates to a process for purification of palonosetron or its salt substantially free of its R-isomer and structure related impurities.

Abstract: Improved organophotoreceptor comprises an electrically conductive substrate and a photoconductive element on the electrically conductive substrate, the photoconductive element comprising: (a) a charge transport material having the formula where Y1 and Y2 are, each independently, an arylamine group; R1 and R2 comprise, each independently, H, an alkyl group, an alkenyl group, a heterocyclic group, or an aromatic group; X1 and X2, each independently, are bridging groups; E1 and E2 are, each independently, an epoxy group; and Z is a linking group comprising an alkyl group, an alkenyl group, a heterocyclic group, or an aromatic group; and (b) a charge generating compound. The charge transport materials can be crosslinked to a polymeric bind, either directly or through a crosslinking agent. Corresponding electrophotographic apparatuses and imaging methods are described.

Abstract: Improved organophotoreceptor comprises an electrically conductive substrate and a photoconductive element on the electrically conductive substrate, the photoconductive element comprising: (a) a charge transport material having the formula, where R comprises a hydrogen, an alkyl group, an alkenyl group, a heterocyclic group, or an aromatic group; X comprises an arylamine group; and Y comprises a 9-fluorenylidene group having at least a solubilizing substituent; and (b) a charge generating compound. Corresponding electrophotographic apparatuses and imaging methods are described.